Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
复制标题
DOI：
10.1080/21645515.2015.1122146
复制
发表时间：
2016-05-03
影响因子：
4.8
通讯作者：
Herman P
中科院分区：
文献类型：
--
作者：
Baldo A;Galanis E;Tangy F;Herman P
减毒麻疹病毒(MV)是目前最有效、最安全的疫苗之一，是预防传染病的理想候选载体。减毒MV已经具备了利用补体调节因子CD46作为主要受体介导病毒入侵和细胞间融合的能力。因此，减毒的MV毒株优先感染和破坏多种癌细胞，使它们也具有吸引力的溶瘤载体。重组MV载体的使用必须符合各种法规要求，特别是与评估对人类健康和环境的潜在风险有关的要求。本文重点介绍了用于疫苗接种和病毒治疗的MV和重组MV载体的主要特点，并从生物安全的角度对这些特点进行了讨论。
Attenuated measles virus (MV) is one of the most effective and safe vaccines available, making it attractive candidate vector to prevent infectious diseases. Attenuated MV have acquired the ability to use the complement regulator CD46 as a major receptor to mediate virus entry and intercellular fusion. Therefore, attenuated MV strains preferentially infect and destroy a wide variety of cancer cells making them also attractive oncolytic vectors. The use of recombinant MV vector has to comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The present article highlights the main characteristics of MV and recombinant MV vectors used for vaccination and virotherapy and discusses these features from a biosafety point of view.